American Bio Medica Corporation
ABMC · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $4 | $4 |
| % Growth | -58.8% | -46.5% | 13.5% | – |
| Cost of Goods Sold | $1 | $2 | $3 | $2 |
| Gross Profit | -$0 | $1 | $1 | $1 |
| % Margin | -21.1% | 24.7% | 29.9% | 32.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $2 | $2 | $2 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -136% | -53.2% | -15% | -16.2% |
| Other Income/Exp. Net | -$0 | $1 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$0 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$1 | -$0 | -$1 | -$1 |
| % Margin | -154.4% | -20.9% | -19.2% | -18.6% |
| EPS | -0.029 | -0.011 | -0.022 | -0.021 |
| % Growth | -172.2% | 51.8% | -7.2% | – |
| EPS Diluted | -0.029 | -0.011 | -0.022 | -0.021 |
| Weighted Avg Shares Out | 48 | 43 | 36 | 33 |
| Weighted Avg Shares Out Dil | 48 | 43 | 36 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$0 | -$1 | -$0 |
| % Margin | -127.4% | -9% | -13% | -9.3% |